Last $0.10 USD
Change Today -0.0095 / -9.09%
Volume 949.7K
ISCO On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Snapshot

Open
$0.10
Previous Close
$0.10
Day High
$0.11
Day Low
$0.10
52 Week High
12/12/13 - $0.30
52 Week Low
07/9/14 - $0.06
Market Cap
19.7M
Average Volume 10 Days
1.2M
EPS TTM
$-0.06
Shares Outstanding
207.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERNATIONAL STEM CELL CORP (ISCO)

international stem cell corp (ISCO) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCO) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCO) Details

International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and biomedical products worldwide. Its products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. The company develops cell types, such as neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat congenital and acquired liver diseases; islet cells for the treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. It also offers cosmetic skin care products through professional channels and distributors, as well as through a branded Website; and human cell culture products for use in pharmaceutical, academic, and government research organizations. The company’s human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines to study breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company offers its human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 03/21/14
Founded in 2001

international stem cell corp (ISCO) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $258.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $220.0K
Chief Scientific Officer and Director
Total Annual Compensation: $182.0K
Compensation as of Fiscal Year 2013.

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Inks Deal Including Certain Terms for Definitive License Agreement with Rohto Pharmaceutical

International Stem Cell (ISCO) has entered into a research agreement with Rohto Pharmaceutical (Rohto). As part of the deal, Rohto will assess stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. The company said that if the research is successful and the parties agree on remaining terms, it is expected that a definitive license agreement will be signed at the end of the twelve-month period of this research agreement. ISCO EVP of Business Development Simon Craw said under the terms of the agreement Rohto will begin working with ISCO provided cells immediately and if the program is successful the company may move to the next stage, signing a definitive license agreement. The deal will see ISCO offer a number of differentiated human cells derived from the company's collection of pluripotent human stem cells known as UniStemCell.

International Stem Cell Corporation Enters into Research Agreement with Rohto Pharmaceutical Co., Ltd

International Stem Cell Corporation (ISCO) announced that it has entered into a research agreement with Rohto Pharmaceutical Co., Ltd. Under this agreement, Rohto will evaluate stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. If the research is successful and the parties agree on remaining terms, it is anticipated that a definitive license agreement will be signed at the end of the twelve-month period of this research agreement. Certain key terms of such a license agreement, including the target disease areas and intellectual property rights, have been established in the research agreement. Under the agreement ISCO will provide a number of differentiated human cells derived from the company's collection of pluripotent human stem cells known as UniStemCell(TM). The company has a track record of successfully demonstrating that human cells derived from UniStemCell(TM) are effective in animal models of various diseases and have the potential to be used as a basis for developing human therapies.

International Stem Cell Corporation Completes Acute Toxicity Study in Parkinson's Disease Program

International Stem Cell Corporation (ISCO) announced the completion of the acute toxicity study of the company's proposed clinical product to treat Parkinson's disease. The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO's proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans. The program continues to progress according to the plan outlined with the FDA at the pre-IND meeting as reported in February 2014. The company intends to provide a further update early next quarter. The study consisted of 19 immune deficient rodents divided into four cohorts, a control group and three treatment groups receiving escalating doses of human parthenogenetic neural stem cells (hPNSC). Animals received stereotactic injections of hPNSC in the striatum and substantia nigra. The rodents were observed for seven days post transplantation and demonstrated normal appearance and behaviors. Necropsies showed no abnormal tissues or tumors after sacrifice. Detailed immunohistochemical analysis demonstrated that the majority of the implanted cells survived the surgery and engrafted into the host brain tissue. ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to differentiate into dopaminergic (DA) neurons and express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $0.10 USD -0.0095

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.03 USD -0.0031
BioTime Inc $2.64 USD +0.05
Cytori Therapeutics Inc $2.13 USD +0.07
ReNeuron Group PLC 3.39 GBp -0.045
StemCells Inc $1.70 USD +0.05
View Industry Companies
 

Industry Analysis

ISCO

Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit www.internationalstemcell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.